Ning Ding

发表

Conjugate of structurally reassigned pneumococcal serotype 31 polysaccharide with CRM197 elicited potent immune response.

Chengli Zong, Huiting Li, Tiantian Sun, 2022, Carbohydrate polymers.

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia.

Yu Cao, H. Zhou, Nianguang Li, 2022, Bioorganic & medicinal chemistry.

Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.

Shan-Liang Sun, Nianyu Li, Zhi-Hao Shi, 2022, Journal of medicinal chemistry.

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.

P. Zhang, Shaopeng Yu, J Wu, 2023, European journal of medicinal chemistry.

Design and synthesis of selective FLT3 inhibitors via exploration of back pocket II.

Nan Li, Nianguang Li, Weichen Dai, 2023, Future Medicinal Chemistry.

Non-coding RNAs as therapeutic targets in cancer and its clinical application

Xin Xue, Jing-Jing Wang, Ning Ding, 2024, Journal of pharmaceutical analysis.

Natural products as potential lead compounds to develop new antiviral drugs over the past decade.

Jin Yang, J Wu, Nianyu Li, 2023, European journal of medicinal chemistry.

Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.

Xin Xue, Ning Ding, Xue-jiao Leng, 2024, European journal of medicinal chemistry.

Exploring drug repositioning possibilities of kinase inhibitors via molecular simulation.

Jing-Jing Wang, Ning Ding, Zhen Tong, 2024, Molecular informatics.